David Sable, MD directs healthcare and life science investing for the Special Situations Funds and is portfolio manager of the Special Situations Life Sciences Fund. After graduating from the Wharton School and the University of Pennsylvania School of Medicine, he trained in obstetrics and gynecology at New York Hospital - Cornell Medical Center, and in reproductive endocrinology at the Brigham and Women's Hospital. He co-founded and served as director of the Institute for Reproductive Medicine and Science at Saint Barnabas Medical Center in New Jersey, was a co-founder of Reprogenetics, which was acquired in 2015, and was founder and CEO of Assisted Reproductive Medical Technologies, a private company that was acquired in 1999.
After leaving clinical medicine, Dr. Sable managed a proprietary healthcare portfolio at Deutsche Bank before joining the Special Situations Funds. Dr. Sable is an adjunct in the department of biology at Columbia University, and teaches “Entrepreneurship in Biotechnology” at Columbia’s Graduate School of Arts and Sciences. He has lectured on healthcare investing, policy, and biotechnology business development at the Wharton School, NYU, Rockefeller University and Rutgers; has delivered keynote addresses to the American Fertility Society, the Texas Fertility Society and the Mexican Fertility Society; and appeared on the CBS Morning News, ABC World News Tonight, NY1 News and PBS’ Nova. He serves on the board of directors of Progyny, a venture-backer medical services company, and for the nonprofit organization Resolve, and is a member of the clinical advisory board for Ovascience, a Massachusetts-based public company developing advanced treatments for infertility. In addition to his academic publications, he has written for the Newark Star-Ledger, Yoga Journal, Xconomy, Genetic Engineering and Biotechnology News, Wharton Magazine, the Columbia Spectator, and writes the “…and other secrets of the buy side” and the "...and other things I learned as an IVF doc" blogs for Forbes Magazine.